EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

蛋白酶激活受体 (PAR) 拮抗剂的评价

• 批准号: 8173270
• 负责人: Andras Gruber
• 金额: $ 4.76万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8173270
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Area; Computer Retrieval of Information on Scientific Projects Database; Disease; Evaluation; F2R gene; Funding; Grant; Hemostatic function; Institution; Proteinase-Activated Receptors; Research; Research Personnel; Research Project Grants; Resources; Source; Testing; Therapeutic; Thrombosis; United States National Institutes of Health; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We continue our collaborative research with Bayer Schering Pharma in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, five compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, three compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 我们继续与拜耳先灵制药在血栓形成和止血领域的合作研究。我们正在参与一项研究项目，以获得拜耳提供的PAR 1拮抗剂是否具有治疗血栓栓塞性疾病的治疗潜力的明确信息。首先，将对5种化合物进行离体评价，并对1种化合物进行体内试验。随后，将对三种化合物进行离体评价，并对两种化合物进行体内评价。